Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | OSBP | P22059 | 1/20 | 0.64 |
| ▸ | RORC | P51449 | 1/20 | 0.64 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 14/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.59 |
| ▸ | POLA1 | P09884 | 1/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 12/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8605712 | 0.92 | CYP46A1 (0.64) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL15321270 | 0.91 | CYP46A1 (0.63) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL7741660 | 0.89 | USP2 (0.70) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL17765070 | 0.89 | CYP46A1 (0.61) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL17765069 | 0.89 | CYP46A1 (0.61) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL10627078 | 0.89 | CYP46A1 (0.61) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL4284415 | 0.89 | USP2 (0.69) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL1243707 | 0.88 | USP2 (0.66) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL21332145 | 0.87 | USP2 (0.63) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL3508152 | 0.86 | CYP46A1 (0.71) | CYP46A1USP2LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550452-B2 | Cationic lipids and use thereof | GOODGENE, INC. (KR) | 2009-06-23 | — | — | US | claimed |
| US-7550452-B2 | Cationic lipids and use thereof | GOODGENE, INC. (KR) | 2009-06-23 | — | — | US | disclosed |
| US-20040185090-A1 | Cationic lipids and use thereof | GOODGENE, INC. (KR) | 2004-09-23 | — | — | US | disclosed |
| WO-2002024627-A1 | CATIONIC LIPIDS AND USE THEREOF | GOODGENE INC. (KR) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040185090-A1 | Cationic lipids and use thereof | CETP, NPC1L1, LIPA | CYP46A1 824/4885USP2 4596/4885LMNA 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.